By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AzurRx BioPharma 

760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn  New York  11226  U.S.A.
Phone: 646-699-7855 Fax: n/a


AzurRx BioPharma, Inc. aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infection. The company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France.


CEO: Thijs Spoor

CSO: Daniel Dupret


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: AzurRx BioPharma
Symbol: AZRX

Company News
AzurRx BioPharma (AZRX) Reaches 6th Patient Enrollment Of Phase IIa Trial Of MS1819 For Treatment Of Exocrine Pancreatic Insufficiency Associated With Chronic Pancreatitis 8/23/2017 8:39:19 AM
AzurRx BioPharma (AZRX) Announces Closing Of $5 Million Private Financing 6/8/2017 10:40:25 AM
AzurRx BioPharma (AZRX) Announces Addition Of Charles J Casamento To The Board Of Directors 3/8/2017 8:28:21 AM
AzurRx BioPharma (AZRX) Announces First Three Patients Included In Phase Ila Study With MS1819-SD For Endocrine Pancreatic Insufficiency 12/21/2016 9:16:29 AM
AzurRx BioPharma (AZRX) Announces Agreement In Principle With Transchem For MTAN Inhibition Technology 12/6/2016 7:49:52 AM
AzurRx BioPharma (AZRX) CEO Provides Shareholders With A "State Of The Union" Communication 12/1/2016 7:24:41 AM
AzurRx BioPharma (AZRX) And Mayoly Spindler Announce Initiation Of Phase II Clinical Trial Of MS1819-SD For Exocrine Pancreatic Insufficiency In Chronic Pancreatitis Patients 11/17/2016 7:45:55 AM
AzurRx BioPharma (AZRX) Announces Pricing Of Initial Public Offering 10/12/2016 11:16:35 AM